ClinConnect ClinConnect Logo
Search / Trial NCT00002080

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

Launched by PHARMACIA · Aug 30, 2001

Trial Information

Current as of March 23, 2025

Completed

Keywords

Rifabutin Acquired Immunodeficiency Syndrome Aids Related Complex Mycobacterium Avium Complex Bacteremia

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Any medication with the exception of other investigational drugs not available under a treatment IND, expanded access, or parallel track program.
  • Patients must have:
  • Confirmed HIV infection.
  • CD4 cell counts \<= 200 cells/mm3.
  • No evidence of disseminated MAC disease.
  • Informed consent of parent or guardian if 12 to \< 18 years of age.
  • NOTE:
  • Pregnant females may be eligible. There are no studies of the safety or efficacy of rifabutin in pregnant women. Rifabutin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In addition, a risk/benefit decision should consider the likelihood of a woman's developing MAC if she does not receive prophylaxis. The risk of developing MAC rises substantially for women with CD4 counts less than 100, although it can also develop in women with higher CD4 counts. Women of reproductive potential who are not pregnant must use contraception. They are encouraged to use means other than oral contraceptives.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms and conditions are excluded:
  • Known hypersensitivity to rifabutin, rifampin, or other rifamycins.
  • Current infection due to MAC or other mycobacterial disease, or complaints consistent with tuberculosis.
  • Concurrent Medication:
  • Excluded:
  • Other investigational drugs with the exception of those available under a treatment IND, expanded access, or parallel track program. (Licensed products prescribed for unlabeled indications are not considered investigational.)
  • Patients with the following prior conditions are excluded:
  • Prior infection due to MAC or other mycobacterial disease or complaints consistent with tuberculosis.

About Pharmacia

Pharmacia is a global biopharmaceutical company dedicated to advancing healthcare through innovative research and development. With a strong focus on delivering effective therapies for a range of medical conditions, Pharmacia harnesses cutting-edge science and technology to create solutions that enhance patient outcomes. The company is committed to conducting rigorous clinical trials that adhere to the highest ethical and scientific standards, ensuring the safety and well-being of participants while contributing to the advancement of medical knowledge. Through collaboration with healthcare professionals and regulatory bodies, Pharmacia strives to bring transformative treatments to market that address unmet medical needs and improve the quality of life for patients worldwide.

Locations

Saint Davids, Pennsylvania, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials